Quantum BioPharma regains Nasdaq compliance through $450k debt settlement with executives.

Quantum BioPharma has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing. The company completed $450,000 in debt settlements with executives Anthony Durkacz, Zeeshan Saeed, and Donal Carroll by issuing 248,160 Class B shares at $5.44 each. These transactions, considered related-party dealings, utilized exemptions from Canadian securities laws, avoiding the need for minority shareholder approval.